Extendicare Inc.

OTCPK:EXET.F Stock Report

Market Cap: US$1.8b

Extendicare Valuation

Is EXET.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of EXET.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: EXET.F ($19.21) is trading above our estimate of future cash flow value ($17.33)

Significantly Below Future Cash Flow Value: EXET.F is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXET.F?

Key metric: As EXET.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EXET.F. This is calculated by dividing EXET.F's market cap by their current earnings.
What is EXET.F's PE Ratio?
PE Ratio25.8x
EarningsCA$96.66m
Market CapCA$2.50b

Price to Earnings Ratio vs Peers

How does EXET.F's PE Ratio compare to its peers?

The above table shows the PE ratio for EXET.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.6x
ARDT Ardent Health
9.7x11.70%US$1.3b
USPH U.S. Physical Therapy
54.6x30.27%US$1.2b
NHC National HealthCare
20.2xn/aUS$2.4b
SEM Select Medical Holdings
14.1x-3.25%US$2.0b
EXET.F Extendicare
25.8xn/aUS$2.5b

Price-To-Earnings vs Peers: EXET.F is expensive based on its Price-To-Earnings Ratio (25.8x) compared to the peer average (24.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does EXET.F's PE Ratio compare vs other companies in the US Healthcare Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.9x-117.81%US$431.05m
NIVF NewGenIvf Group
0.07x44.27%US$1.17m
IMTH AnTix Holdings
0.09xn/aUS$108.15k
CMAX.Q CareMax
n/a77.17%US$3.00
No more companies available in this PE range
EXET.F 25.8xIndustry Avg. 22.1xNo. of Companies11PE01632486480+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EXET.F is expensive based on its Price-To-Earnings Ratio (25.8x) compared to the US Healthcare industry average (22.3x).

Price to Earnings Ratio vs Fair Ratio

What is EXET.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXET.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EXET.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EXET.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.21
US$22.87
+19.06%
6.07%US$25.60US$21.94n/a5
Mar ’27US$19.81
US$22.20
+12.05%
10.52%US$25.66US$18.33n/a5
Feb ’27US$17.24
US$18.19
+5.49%
9.86%US$21.61US$16.39n/a5
Jan ’27US$15.54
US$17.54
+12.93%
13.44%US$21.74US$13.77n/a6
Dec ’26US$14.60
US$15.77
+8.00%
11.12%US$17.72US$13.46n/a3
Nov ’26US$11.51
US$11.92
+3.55%
9.93%US$14.28US$10.71n/a8
Oct ’26US$10.87
US$11.95
+9.92%
9.91%US$14.47US$10.85n/a8
Sep ’26US$9.51
US$11.80
+24.14%
10.08%US$14.48US$10.86n/a7
Aug ’26US$8.93
US$11.68
+30.81%
10.86%US$14.62US$10.60n/a7
Jul ’26US$10.37
US$11.62
+12.10%
11.55%US$14.45US$10.48n/a6
Jun ’26US$10.51
US$11.62
+10.58%
11.55%US$14.45US$10.48n/a6
May ’26US$10.13
US$10.38
+2.51%
8.97%US$11.92US$9.39n/a6
Apr ’26US$8.99
US$9.36
+4.07%
9.32%US$10.88US$7.95n/a6
Mar ’26US$8.76
US$8.67
-1.00%
13.24%US$10.89US$7.60US$19.816
Feb ’26US$7.30
US$7.62
+4.45%
3.21%US$7.97US$7.28US$17.244
Jan ’26US$7.27
US$7.85
+7.96%
3.71%US$8.21US$7.49US$15.543
Dec ’25US$7.56
US$7.85
+3.82%
3.71%US$8.21US$7.49US$14.603
Nov ’25US$6.55
US$7.15
+9.21%
2.44%US$7.40US$7.03US$11.513
Oct ’25US$7.00
US$7.15
+2.19%
2.44%US$7.40US$7.03US$10.873
Sep ’25US$6.42
US$6.94
+8.14%
4.30%US$7.31US$6.58US$9.513
Aug ’25US$5.74
US$6.12
+6.57%
2.83%US$6.24US$5.87US$8.933
Jul ’25US$5.42
US$6.12
+12.90%
2.83%US$6.24US$5.87US$10.373
Jun ’25US$5.44
US$6.12
+12.45%
2.83%US$6.24US$5.87US$10.513
May ’25US$5.32
US$5.93
+11.49%
5.10%US$6.30US$5.56US$10.133
Apr ’25US$5.68
US$5.93
+4.46%
5.10%US$6.30US$5.56US$8.993
Mar ’25US$5.02
US$5.44
+8.34%
2.82%US$5.62US$5.25US$8.763
US$22.74
Fair Value
15.5% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 19:56
End of Day Share Price 2026/03/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Extendicare Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle McPheeATB Cormark
Tom CallaghanBMO Capital Markets Equity Research
Tania Armstrong-WhitworthCanaccord Genuity